Navigating Anthem (Elevance Health) Evrysdi Prior Authorization

Evrysdi and Anthem's Pharmacy Benefit Management

Evrysdi (risdiplam), an oral medication for Spinal Muscular Atrophy (SMA), typically falls under the pharmacy benefit. For Anthem-licensed plans, prior authorization for such specialty drugs is managed by CarelonRx, Elevance Health's in-house Pharmacy Benefit Manager (PBM). This distinction is critical for identifying the correct submission pathways and policy criteria.

Prior Authorization Submission Channels for Evrysdi with Anthem

• CarelonRx's proprietary provider prior authorization portal for pharmacy benefit submissions.
• CoverMyMeds for electronic prior authorization (ePA) submissions, integrated with CarelonRx.
• Surescripts for electronic prior authorization (ePA) submissions, integrated with CarelonRx.

Accessing Evrysdi Clinical Criteria and Utilization Policies

Understanding the specific clinical criteria for Evrysdi is essential for successful prior authorization. While Anthem operating companies publish general medical policies via provider sites accessed through Availity, specific formulary and utilization management (UM) criteria for pharmacy-benefit drugs like Evrysdi are managed by CarelonRx. Review state-specific Medicaid and Medicare Advantage variants for tailored criteria, as policies may align with the Elevance Health corporate framework but have local adaptations.

Turnaround Time Considerations for Evrysdi PA with Anthem

Prior authorization decision timeframes for Evrysdi with Anthem-licensed plans vary by line of business and state regulations. For Medicare Advantage and Medicaid managed care plans, Anthem is an impacted payer under CMS-0057-F, which mandates 72-hour standard and 24-hour expedited decision timeframes on a phased compliance timeline. Commercial plans are subject to state-specific insurance regulations for PA turnaround, which can vary materially across the states where Anthem operates.

Common Denial Reasons for Evrysdi with Anthem

• Medical necessity criteria not satisfied or inadequate clinical documentation to support treatment.
• Non-adherence to step therapy protocols or formulary requirements as outlined by CarelonRx.
• Lack of specific information to support the requested dosage, duration, or patient-specific factors.
• Non-formulary drug status, potentially requiring a formulary exception request.

Evrysdi Prior Authorization Appeal Pathways

Denials for **Anthem (Elevance Health) Evrysdi prior authorization** often stem from specific clinical or administrative gaps. Appeals for pharmacy benefit denials typically follow the standard Anthem operating-company appeals process, often managed through CarelonRx's systems. Providers can generally access peer-to-peer reviews to discuss clinical rationale with a plan medical director, which can be an effective pathway to overturn denials based on medical necessity or documentation clarity.